At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 801 enrolled
Drug / intervention
Delgocitinibdrug
Likely dose
Delgocitinib 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Extension Trial of DELTA 1 and DELTA 2 to Evaluate the Long-term Safety of a Twice-daily Treatment With Delgocitinib Cream 20 mg/g as Needed for up to 36 Weeks in Adult Subjects With Chronic Hand Eczema (DELTA 3)
In Brief
A Phase 3 clinical trial evaluating Delgocitinib for Chronic Hand Eczema. Completed, enrolled 801 participants across 95 sites in 10 countries.
Detailed Summary
The purpose of this extension trial is to evaluate the long-term safety of delgocitinib. Subjects will visit the clinic every 4 week to assess the safety and efficacy of the treatment, until Week 36. A final follow-up phone call is planned on Week 38.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hand Eczema
CountriesBelgium, Canada, Denmark, France, Germany, Italy, Netherlands, Poland, Spain, United Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
First PostedJul 2021
Enrollment StartAug 2021
Primary CompletionSep 2023
TodayJul 2026
First PostedJul 2, 2021
Enrollment StartAug 23, 2021
Primary CompletionSep 18, 2023
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 5 years ago
Interventions
Delgocitinibdrug
Delgocitinib cream 20 mg/g